Discovery of N-(Pyridin-4-yl)-1,5-naphthyridin-2-amines as Potential Tau Pathology PET Tracers for Alzheimer's Disease

J Med Chem. 2017 Feb 23;60(4):1272-1291. doi: 10.1021/acs.jmedchem.6b01173. Epub 2017 Feb 10.

Abstract

A mini-HTS on 4000 compounds selected using 2D fragment-based similarity and 3D pharmacophoric and shape similarity to known selective tau aggregate binders identified N-(6-methylpyridin-2-yl)quinolin-2-amine 10 as a novel potent binder to human AD aggregated tau with modest selectivity versus aggregated β-amyloid (Aβ). Initial medicinal chemistry efforts identified key elements for potency and selectivity, as well as suitable positions for radiofluorination, leading to a first generation of fluoroalkyl-substituted quinoline tau binding ligands with suboptimal physicochemical properties. Further optimization toward a more optimal pharmacokinetic profile led to the discovery of 1,5-naphthyridine 75, a potent and selective tau aggregate binder with potential as a tau PET tracer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / diagnostic imaging*
  • Amination
  • Amyloid beta-Peptides / analysis*
  • Animals
  • Brain / diagnostic imaging*
  • Haplorhini
  • Humans
  • Mice
  • Naphthyridines / chemistry*
  • Naphthyridines / pharmacokinetics
  • Positron-Emission Tomography / methods*
  • Protein Aggregation, Pathological / diagnostic imaging*
  • Rats
  • tau Proteins / analysis*

Substances

  • Amyloid beta-Peptides
  • Naphthyridines
  • tau Proteins